^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    topotecan

    i
    Other names: NK 211, NK-211, NK211, NSC 609699, SKF 104864
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    1d
    N2013-02: Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    sorafenib • cyclophosphamide • topotecan
    6d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline | Trial completion date: Jan 2030 --> Jul 2030 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Jul 2030
    Trial completion date • Trial initiation date • Trial primary completion date • Platinum resistant
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    7d
    Design, synthesis and docking studies of new benzothiophene and benzothienopyran derivatives as topoisomerase I inhibitors with potential immunomodulatory action via cGAS-STING signaling pathway. (PubMed, Bioorg Chem)
    Additionally, drug-likeness and pharmacokinetic properties, predicted by SwissADME, indicated that 5c complies with Lipinski's and Veber's rules of oral bioavailability showing a bioavailability score of 0.55. These findings highlight compound 5c as a promising Topo I inhibitor with mechanistically validated multimodal anticancer activity, superior inhibitory potency compared with topotecan, and enhanced selectivity toward cancer cells over normal CD8+ cells, supporting its potential for further anticancer drug development.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    topotecan
    8d
    NCI-2022-03215: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | N=60 --> 18 | Trial primary completion date: Apr 2027 --> Feb 2026
    Enrollment change • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan
    12d
    NCI-2022-03215: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan
    18d
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=420, Recruiting, GlaxoSmithKline | N=300 --> 420
    Enrollment change
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    20d
    Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    RAD51 (RAD51 Homolog A)
    |
    carboplatin • veliparib (ABT-888) • topotecan
    20d
    COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2/3, N=582, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    21d
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    25d
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    29d
    RAINFOL-02: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    FOLR1 expression • BRCA mutation
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    29d
    innovaTV 301: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=502, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Tivdak (tisotumab vedotin-tftv)